Notch activation inhibits AML growth and survival: a potential therapeutic approach
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets are remarkably low, suggesting that Notch is present but not constitutively activated in human AML. The functional role of these Notch receptors in AML is not known. Induced activation through any of the Notch receptors (Notch1–4), or through the Notch target Hairy/Enhancer of Split 1 (HES1), consistently leads to AML growth arrest and caspase-dependent apoptosis, which are associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression. These effects were dependent on the HES1 repressor domain and were rescued through reexpression of BCL2. Importantly, activated Notch1, Notch2, and HES1 all led to inhibited AML growth in vivo, and Notch inhibition via dnMAML enhanced proliferation in vivo, thus revealing the physiological inhibition of AML growth in vivo in response to Notch signaling. As a novel therapeutic approach, we used a Notch agonist peptide that led to significant apoptosis in AML patient samples. In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, Notch signaling functions as a tumor suppressor in the malignancies of myeloid origin, such as acute myelogenous leukemia and chronic myeloid leukemia [138, 139].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [138]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“…independent of which activated receptor was expressed, suggesting that a common downstream target expression had no effect on T-ALL cell line growth, whereas Notch inhibition via expression of dnMAML inhibited the growth of the MOLT4 and SUPT1 T-ALL lines, as expected (Weng et al., 2003, 2004).”
BackgroundResultProduction of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266 · cited 1×
“The production of retroviral supernatant and transduction of each cell line was performed following previously established methods (Pear et al., 1993).”
MethodEllisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., & Sklar, J. (1991) · Cell · doi:10.1016/0092-8674(91)90111-b · Cited by 1,696
Notch1 Expression in Early Lymphopoiesis Influences B versus T Lineage Determination
Pui, J. C., Allman, D., Xu, L., DeRocco, S., Karnell, F. G., Bakkour, S., Lee, J. Y., Kadesch, T., Hardy, R. R., Aster, J. C., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80105-3 · Cited by 949
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718 · cited 1×
“We probed a validated reversephase protein lysate array (RPPA) containing duplicate dilutions of total cell lysates from 560 AML patient samples, 10 normal CD34-selected controls, and 21 normal peripheral blood mononuclear cell controls (Tibes et al., 2006; Kornblau and Coombes, 2011).”
MethodSelf-citationPucci, B., Kasten, M., & Giordano, A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900101 · Cited by 652
Saito, T., Chiba, S., Ichikawa, M., Kunisato, A., Asai, T., Shimizu, K., Yamaguchi, T., Yamamoto, G., Seo, S., Kumano, K., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00111-0 · Cited by 561
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Harrison, H., Farnie, G., Howell, S. J., Rock, R. E., Stylianou, S., Brennan, K. R., Bundred, N. J., & Clarke, R. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1681 · Cited by 543 · cited 1×
“Interestingly, AML and normal CD34+ cells expressed similar levels of Notch receptors 1–3, but AML samples expressed significantly higher Notch4, the Notch receptor classically associated with vascular endothelium (Wu et al., 2005) and breast cancer (Harrison et al., 2010).”
Cited by
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
Kode, A., Manavalan, J. S., Mosialou, I., Bhagat, G., Rathinam, C. V., Luo, N., Khiabanian, H., Lee, A., Murty, V. V., Friedman, R., et al. (2014) · Nature · doi:10.1038/nature12883 · Cited by 532
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.018 · Cited by 374
Metadata
- Authors
- Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., Akers, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., Melnick, A. M., Figueroa, M. E., & Zweidler-McKay, P. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Pediatric Hematology/Oncology, M.D. Anderson Cancer Center Orlando, Orlando, FL 32806 4
- Cook Children's Medical Center (US)
- Sigma Genosys (United States) (US)
- Weill Cornell Medicine (US)
- Department of Pathology, University of Michigan Health System, Ann Arbor, MI 48109 8
- Division of Pediatrics 1 , 2 , and 3
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-01-28
- Volume
- 210
- Issue
- 2
- Pages
- 321-337
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3570106
- OpenAlex
- W2113096952
- Cited by
- 152
- References
- 59
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 8 · 2020: 8 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 15 · 2015: 18 · 2014: 20 · 2013: 10
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA138816, P30CA016672)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- Notch signaling, acute myeloid leukemia, Notch1, Notch2, Notch3, Notch4, Hes1, apoptosis, Bcl-2, therapeutic target
- MeSH terms
- Transcription Factor HES-1, Adolescent, Animals, Cell Survival, Child, DNA-Binding Proteins, Humans, Infant, Mutation, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Signal Transduction, Leukemia, Myeloid, Acute, Gene Expression, Tumor Suppressor Protein p53, Mice, SCID, Mice, Inbred NOD, Apoptosis, Mice, Knockout, Homeodomain Proteins, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Receptors, Notch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.